{"id":80883,"date":"2020-11-03T09:50:40","date_gmt":"2020-11-03T14:50:40","guid":{"rendered":"https:\/\/decisionresourcesgroup.com\/?p=80883"},"modified":"2024-07-05T16:45:00","modified_gmt":"2024-07-05T16:45:00","slug":"whats-driving-oncology-htas-south-korea","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/whats-driving-oncology-htas-south-korea\/","title":{"rendered":"What\u2019s driving oncology HTAs in South Korea?"},"content":{"rendered":"

Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency\u00a0 (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA.<\/p>\n

To help pharma companies plan clinical trials and economic evidence submission in order to achieve favorable access in South Korea, we used the Context Matters Market Access Platform<\/a> to analyze the clinical and economic rationales behind HIRA\u2019s decisions for 15 oncology indications over the past 5 years (2015 \u2013 2019):<\/p>\n

4 in 5 decisions valid adequacy of benefit<\/strong>
\nHIRA benefit assessment decisions in South Korea, from HTA reports across 15 oncology indications, 2015-2019<\/em><\/p>\n

The vast majority of decisions received valid adequacy of benefit. In a few cases, decisions were considered non-benefit which means that the drugs are not eligible for price negotiations in South Korea.<\/em>\u00a0<\/em><\/p>\n

\"\"<\/a><\/p>\n

Source: Context Matters’ Market Access Platform, Accessed March 8, 2020, Decision Resources Group<\/em>\u00a0<\/strong><\/p>\n

 <\/p>\n

Favorable reimbursement tied to improved efficacy and acceptable cost-effectiveness<\/strong>
\nKey clinical and economic rationales behind agency\u2019s decision, HTA reports across 15 oncology indications, 2015-2019<\/em>\u00a0<\/em><\/p>\n

\"\"<\/a><\/p>\n

Source: Context Matters’ Market Access Platform, Accessed March 8, 2020, Decision Resources Group<\/em><\/p>\n

Across decisions, favorable reimbursement was tied to improved efficacy and acceptable cost-effectiveness (commonly through a risk-sharing agreement). Direct cost-comparison was the most frequently used economic model. Some medicinal products under review, registered in > 3 foreign countries, were classified as drugs that can omit the submission of economic evaluation documents.<\/p>\n

However, some therapies that cleared the efficacy hurdle fell short in terms of demonstrated cost-effectiveness, leading to unfavorable decisions on the part of HIRA. HIRA does not have a formal cost-effectiveness threshold, but implicitly, the threshold is approximately KRW 25 million for all drugs (US$22,000) and KRW 50 million for oncology or rare drugs.<\/p>\n

 <\/p>\n

What does this mean for pharma companies assessing this market?<\/h4>\n

The research indicates that oncology product manufacturers should provide robust clinical data to show better clinical outcome results and strong economic data to demonstrate drug cost-effectiveness to gain market access in South Korea.<\/p>\n

Risk-sharing agreements and economic evaluation exemptions improve patient accessibility for drugs without alternatives in life-threatening disease conditions. Uncertainties in clinical efficacy\/effectiveness and cost-effectiveness are the key factors correlated with non-benefit.<\/p>\n

Understanding the evidence requirement by the reimbursement agency for clinical and economic decision-making could possibly result in quicker patient access to innovative treatments. South Korea is planning to introduce a post-list review focusing on anticancer and orphan drugs.<\/p>\n","protected":false},"excerpt":{"rendered":"

Reimbursement in South Korea depends upon a favorable review by Health Insurance Review Agency\u00a0 (HIRA), and some therapies may not be reimbursed because of shortcomings from the perspective of HIRA….<\/p>\n","protected":false},"author":33,"featured_media":96106,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[19,21],"tags":[90,84],"class_list":["post-80883","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-life-sciences-healthcare","tag-market-access","tag-oncology","clarivate-product-biopharma"],"acf":[],"lang":"en","translations":{"en":80883},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/80883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=80883"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/80883\/revisions"}],"predecessor-version":[{"id":266309,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/80883\/revisions\/266309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/96106"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=80883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=80883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=80883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}